JP Morgan analyst Mark Strouse maintains Ormat Technologies (NYSE:ORA) with a Neutral and raises the price target from $77 to $80.
Analyst Ratings for Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…